Clin Case Rep Int | Volume 7, Issue 1 | Case Report | Open Access

Safety of Post-Dabigatran, Non-Antidoted Intravenous Thrombolysis for Acute Ischemic Stroke

Chiang HC^1,2, Chang HJ², Hong CT^3,4* and Chan L^3,4

¹Department of Internal Medicine, Division of Neurology Medicine, Sinwu Branch, Taoyuan General Hospital, Ministry of Health and Welfare, Taiwan
²Department of Internal Medicine, Division of Neurology Medicine, Taoyuan General Hospital, Ministry of Health and Welfare, Taiwan
³Department of Neurology, Shuang-Ho Hospital, Taipei Medical University, Taiwan
⁴Department of Neurology, School of Medicine, College of Medicine, Taipei Medical University, Taiwan

^*Correspondance to: Chien-Tai Hong 

Abstract

Dabigatran is one of the novel oral anticoagulants for stroke prevention in people with atrial fibrillation. Although the presence of antidote, availability, and feasibility are still challenging issues. At present, there is no conclusive recommendation regarding the post-dabigatran, non-antidoted intravenous thrombolysis for acute stroke patients. We presented a case of safely application of intravenous thrombolysis to a post-dabigatran, non-antidoted, 84-year-old female with acute nonlarge artery ischemic stroke.

Keywords:

Dabigatran; Antidote; Thrombolysis; Stroke

Citation:

Chiang HC, Chang HJ, Hong CT, Chan L. Safety of Post-Dabigatran, Non- Antidoted Intravenous Thrombolysis for Acute Ischemic Stroke. Clin Case Rep Int. 2023; 7: 1496.